Free tool
FAERS Monitor: Cafcit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020793 or its brand name (Cafcit, Caffeine Citrate). Reports on generic versions are filed under their own applications.
Reports
2,330
Serious
2,271
97% of reports
Hospitalization
1,143
Death reported
1,231
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pemphigus1,007
- hepatic enzyme increased974
- glossodynia972
- pericarditis960
- alopecia954
- hand deformity950
- joint swelling944
- anti-cyclic citrullinated peptide antibody positive931
- rheumatoid arthritis931
- arthropathy925
- discomfort925
- pain924
- fatigue915
- abdominal discomfort909
- systemic lupus erythematosus909
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 8 |
| 2007 | 20 |
| 2008 | 61 |
| 2009 | 19 |
| 2010 | 34 |
| 2011 | 45 |
| 2012 | 47 |
| 2013 | 11 |
| 2014 | 8 |
| 2015 | 9 |
| 2016 | 10 |
| 2017 | 19 |
| 2018 | 113 |
| 2019 | 67 |
| 2020 | 108 |
| 2021 | 234 |
| 2022 | 265 |
| 2023 | 268 |
| 2024 | 407 |
| 2025 | 374 |
| 2026 | 202 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,829 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anti-cyclic citrullinated peptide antibody positiveSignal | 931 | 1347.8 | 1274.9 | 1,089,505 |
| pemphigusSignal | 1,007 | 790.7 | 752.1 | 730,001 |
| hand deformitySignal | 950 | 704.7 | 669.0 | 619,008 |
| pericarditisSignal | 960 | 547.0 | 519.9 | 493,240 |
| glossodyniaSignal | 972 | 409.7 | 389.8 | 379,101 |
| systemic lupus erythematosusSignal | 909 | 237.2 | 225.2 | 208,479 |
| arthropathySignal | 925 | 152.7 | 145.2 | 137,329 |
| discomfortSignal | 925 | 138.9 | 132.1 | 124,986 |
| hepatic enzyme increasedSignal | 974 | 130.8 | 124.6 | 123,960 |
| rheumatoid arthritisSignal | 931 | 74.6 | 71.0 | 67,366 |
| joint swellingSignal | 944 | 71.1 | 67.7 | 65,078 |
| abdominal discomfortSignal | 909 | 49.2 | 46.7 | 42,964 |
| alopeciaSignal | 954 | 44.1 | 42.0 | 40,286 |
| painSignal | 924 | 13.6 | 12.9 | 11,079 |
| fatigueSignal | 915 | 10.6 | 10.1 | 8,261 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.